Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients.

scientific article published on 17 July 2013

Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1155/2013/687176
P8608Fatcat IDrelease_5dke65rgrzeotdqbw2slr6qi7m
P932PMC publication ID3730211
P698PubMed publication ID23956848
P5875ResearchGate publication ID255976849

P50authorQing MaQ42972374
P2093author name stringGene D Morse
Joshua R Sawyer
Chiu-Bin Hsiao
James M Mikula
P2860cites workGuidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panelQ56973152
Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot studyQ83204180
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumoniaQ83711798
Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 WeeksQ34447780
High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count.Q35965800
Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapyQ36428713
The inhibitory quotient. A method for interpreting minimum inhibitory concentration dataQ36658969
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsQ37345610
Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failureQ37693158
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.Q43199280
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trialQ43265110
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.Q43265351
Resistance profile of darunavir: combined 24-week results from the POWER trialsQ46712726
P275copyright licenseCreative Commons Attribution 3.0 UnportedQ14947546
P6216copyright statuscopyrightedQ50423863
P921main subjectdarunavirQ3765251
P304page(s)687176
P577publication date2013-07-17
P1433published inAIDS Research and TreatmentQ26854014
P1476titleComparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients
P478volume2013

Search more.